RESULTS	A significantly lower incidence for rilpivirine vs. efavirenz was observed for the following events : treatment-related grade 2-4 overall adverse events ( 17 vs. 30 % ; P < 0.0001 ) , rash ( any type ; 2 vs. 12 % ; P < 0.0001 ) , and neurological adverse events ( 19 vs. 40 % ; P < 0.0001 ) , including dizziness ( 10 vs. 29 % ; P < 0.0001 ) .\